Read, Watch or Listen

Pfizer announced a $7.3 billion deal to acquire Metsera, a weight-loss drugmaker, aiming to enter the booming obesity market. The acquisition includes an upfront cash payment and contingent value rights based on Metsera's drug development success. Metsera's pipeline includes both oral and injectable treatments, potentially generating over $5 billion in annual sales. This follows Pfizer's setbacks in developing its own obesity drugs, and analysts view this acquisition as a strategic move to accelerate Pfizer's presence in a market projected to reach $100 billion by the 2030s. The deal is expected to close by year-end.

Prepared by Christopher Adams and reviewed by editorial team.